Denali Therapeutics

Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company focuses on developing therapies for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders like Hunter syndrome. Denali employs around 422 professionals and utilizes proprietary blood-brain barrier transport technologies to meet the medical needs of patients with brain-related disorders. Denali's innovative approach includes four engineered transport vehicle systems: Enzyme Transport Vehicle (ETV), Antibody Transport Vehicle (ATV), Protein Transport Vehicle (PTV), and Oligonucleotide Transport Vehicle (OTV). These technologies enable the delivery of various therapeutic agents to the brain. The company collaborates with major pharmaceutical partners, including Sanofi, AbbVie, and Takeda, to enhance the development of its pipeline products, which include DNL310 for Hunter syndrome and DNL151 for Parkinson’s disease. Denali's mission is to advance therapies that address the underlying causes of neurodegeneration, emphasizing a commitment to rigorous science and patient-focused innovation.